Data & Insights 1 min read

Orbisa ON Intercept Pharma

Orbisa ON Intercept Pharma
Share

Orbisa provides robust metrics for the buy-side allowing market participants to validate their short positions. In our latest analytical piece, Orbisa insights shows a striking decline in borrowing demand for Intercept Pharmaceuticals. 

Published October 20, 2022.

Data & Insights

Wanguo’s Golden Run Meets Its Match

Orbisa data shows short sellers building positions in Wanguo Gold as utilization climbed to 91.5% and borrow costs rose sharply following record earnings and a HK$5.5 billion convertible bond announcement.

Learn More

Connecting
Securities Finance

Stay ahead in securities finance with expert insights, market trends, and timely updates.

By subscribing, you agree to our Privacy Policy.